Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.30 +4.5%	$2.30	$0.95 ▼ $2.85	$19.75M	0.13	112,448 shs	126,427 shs
DARE Dare Bioscience	$2.08 -1.9%	$2.43	$1.83 ▼ $9.19	$28.58M	1.11	253,897 shs	110,788 shs
PMN Promis Neurosciences	$0.53 -0.2%	$0.59	$0.38 ▼ $1.59	$27.76M	-0.04	835,657 shs	335,069 shs
SPRB Spruce Biosciences	$8.20 -3.5%	$7.18	$0.06 ▼ $0.61	$4.61M	2.43	802,052 shs	5,615 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	-0.45%	-16.35%	+12.24%	-9.84%
DARE Dare Bioscience	0.00%	-3.64%	-17.51%	-26.90%	-40.28%
PMN Promis Neurosciences	0.00%	-13.14%	-45.68%	+6.12%	-58.78%
SPRB Spruce Biosciences	0.00%	-8.99%	-6.87%	+73.54%	-77.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	3.1008 of 5 stars	3.5	2.0	3.4	0.0	0.0	0.6
DARE Dare Bioscience	2.5169 of 5 stars	3.5	5.0	0.0	2.6	0.0	0.0
PMN Promis Neurosciences	2.3665 of 5 stars	3.5	5.0	0.0	0.0	0.8	0.6
SPRB Spruce Biosciences	2.2643 of 5 stars	3.0	3.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	334.78% Upside
DARE Dare Bioscience	3.00	Buy	$12.00	476.92% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	710.57% Upside
SPRB Spruce Biosciences	2.00	Hold	$131.25	1,500.61% Upside

Current Analyst Ratings Breakdown

Latest SPRB, PMN, DARE, and AYTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81.66M	0.25	N/A	N/A	$4.64 per share	0.50
DARE Dare Bioscience	-$17.70K	-1,584.00	N/A	N/A	($0.69) per share	-3.01
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A
SPRB Spruce Biosciences	$4.91M	0.94	N/A	N/A	$1.88 per share	4.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	11/13/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	11/13/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$99.25	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	11/10/2025 (Estimated)

Latest SPRB, PMN, DARE, and AYTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
DARE Dare Bioscience	N/A	0.34	0.34
PMN Promis Neurosciences	N/A	0.97	0.97
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
DARE Dare Bioscience	6.70%
PMN Promis Neurosciences	50.13%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
DARE Dare Bioscience	4.80%
PMN Promis Neurosciences	6.11%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
DARE Dare Bioscience	30	13.48 million	12.83 million	Not Optionable
PMN Promis Neurosciences	5	51.81 million	48.64 million	Not Optionable
SPRB Spruce Biosciences	20	562,000	37.54 million	Optionable

SPRB, PMN, DARE, and AYTU Headlines

Recent News About These Companies

Head to Head Contrast: Spruce Biosciences (NASDAQ:SPRB) & MusclePharm (OTCMKTS:MSLP)

August 24 at 2:13 AM | americanbankingnews.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Sees Large Growth in Short Interest

August 18, 2025 | americanbankingnews.com

Comparing Spruce Biosciences (NASDAQ:SPRB) & Zomedica (OTC:ZOMDF)

August 18, 2025 | americanbankingnews.com

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 14, 2025 | businesswire.com

Spruce Biosciences to enact 1-for-75 reverse stock split

July 24, 2025 | msn.com

Spruce Biosciences Announces Reverse Stock Split

July 24, 2025 | finance.yahoo.com

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

July 22, 2025 | globenewswire.com

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.comM

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.comB

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.comF

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.comS

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, PMN, DARE, and AYTU Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.30 +0.10 (+4.55%)

Closing price 03:59 PM Eastern

Extended Trading

$2.32 +0.02 (+0.91%)

As of 07:56 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Dare Bioscience NASDAQ:DARE

$2.08 -0.04 (-1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$2.13 +0.05 (+2.64%)

As of 07:51 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Promis Neurosciences NASDAQ:PMN

$0.53 0.00 (-0.24%)

Closing price 03:59 PM Eastern

Extended Trading

$0.55 +0.02 (+2.88%)

As of 07:50 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Spruce Biosciences NASDAQ:SPRB

$8.20 -0.30 (-3.53%)

As of 08/22/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time